-
Mashup Score: 20Early Findings on Ziftomenib With Chemotherapy in AML From KOMET-007 Trial | Blood Cancers Today - 18 hour(s) ago
Ziftomenib plus standard cytarabine and daunorubicin chemotherapy was well tolerated with consistent safety and continued to show robust clinical activity in NPM1-mutated AML.
Source: bloodcancerstoday.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 44Advancing Drug Development in Myelodysplastic Syndromes - 2 day(s) ago
Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of all
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
An very important white paper summarizing thoughts from different stakeholders including academia, FDA, and others from a workshop that debated every aspect of Drug Development in #MDSsm kudos to authors led by myeloid malignancy rising star @dralainmina https://t.co/ko524m9JRC
-
-
Mashup Score: 44Advancing Drug Development in Myelodysplastic Syndromes - 8 day(s) ago
Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of all
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
An very important white paper summarizing thoughts from different stakeholders including academia, FDA, and others from a workshop that debated every aspect of Drug Development in #MDSsm kudos to authors led by myeloid malignancy rising star @dralainmina https://t.co/ko524m9JRC
-
-
Mashup Score: 38Advancing Drug Development in Myelodysplastic Syndromes - 21 day(s) ago
Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of all
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
An very important white paper summarizing thoughts from different stakeholders including academia, FDA, and others from a workshop that debated every aspect of Drug Development in #MDSsm kudos to authors led by myeloid malignancy rising star @dralainmina https://t.co/ko524m9JRC
-
-
Mashup Score: 5
The WHO and International Consensus Classification 2022 classifications of myelodysplastic syndromes enhance diagnostic precision and refine decision-making processes in these diseases. However, some discrepancies still exist and potentially cause inconsistency in their adoption in a clinical setting. We adopted a data-driven approach to provide a harmonisation between these two classification systems. We investigated the importance of genomic features and their effect on the cluster assignment process to define harmonised entity labels.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
@beatalleukemia @ic_MDS This work follows our recent international, data-driven approach to harmonization of #MDSsm classification schema which would also improve consistency of trial eligibility https://t.co/x56ILFnCU2
-
-
Mashup Score: 19Early Findings on Ziftomenib With Chemotherapy in AML From KOMET-007 Trial | Blood Cancers Today - 29 day(s) ago
Ziftomenib plus standard cytarabine and daunorubicin chemotherapy was well tolerated with consistent safety and continued to show robust clinical activity in NPM1-mutated AML.
Source: bloodcancerstoday.comCategories: General Medicine News, Hem/OncsTweet-
Early Findings on Ziftomenib With Chemotherapy in AML From KOMET-007 Trial https://t.co/7s4Iksjmue
-
-
Mashup Score: 25
Dr. Amer Zeidan presents interim Phase 1a results from the KOMET-007 trial, demonstrating the safety and robust clinical activity of ziftomenib combined with intensive chemotherapy (7+3) in newly diagnosed adverse-risk NPM1-mutated and KMT2A-rearranged acute myeloid leukemia, highlighting high response rates and promising survival outcomes.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet-
Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007 https://t.co/mM3kvcTECz via @onclive
-
-
Mashup Score: 42Acute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them - 1 month(s) ago
The advent of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has revolutionized the treatment of acute promyelocytic leukemia (APL), resulting in excellent rates of remission and long-term survival. However, real-world outcomes often fall short of those observed in clinical trials due to various factors related to patient demographics and clinical practices. This review examines APL treatment outcomes in real-world settings and highlights the phenomenon of APL clusters. Clinical trials frequently exclude older patients and individuals with significant comorbidities, yet these groups represent a substantial portion of patients in clinical practice. Early mortality remains high in real-world settings, compounded by delayed diagnosis and treatment initiation, as well as the inexperience of some community providers and limited resources of their centers in managing APL and its associated complications. High rates of disease and induction-related complications further exacerbate
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet-
An outstanding review on #APL by our super star @Yale @YaleMed @YaleIMed @YaleCancer @TradIMYale super star resident @ABidikianMD Acute Promyelocytic Leukemia in Real World: Understanding Outcome Differences & How to Improve https://t.co/T3ZgmXxBFN #mdpicancers via @Cancers_MDPI
-
-
Mashup Score: 4Major PBM reforms feature in Congress' year-end spending bill - 1 month(s) ago
An end-of-year spending bill will include major reforms to the ways pharmacy benefit managers operate, including significant new restrictions on the fees and rebates that have huge influence over the cost of drugs and what products are covered.
Source: endpts.comCategories: General Medicine News, Hem/OncsTweet-
One of the few things that everyone involved in healthcare delivery in USA agree on is curbing the Pharmacy Benefit Managers (PBM). Long overdue legislation but hope to see it passed soon. Major PBM reforms feature in Congress’ year-end spending bill https://t.co/u6MQmNza01
-
-
Mashup Score: 5Insights into Leukemia from Single-Cell Genomics - 1 month(s) ago
Despite its relatively recent emergence, single-cell sequencing has cemented its place in scientific research. It has grown exponentially in less than two decades since its start, with broad impact in the biological sciences. The blood represents an attractive system for early development and application of single-cell technologies. As a result, single-cell analyses in blood and leukemia have led the way in describing how cellular heterogeneity affects cancer progression. In this review, we discuss the technological and conceptual advances brought by single-cell genomics, ranging from genetic evolution and differentiation states that mediate drug resistance to the complex interactions required for immunotherapy responses. These high-resolution insights are starting to enter clinical assessment.
Source: www.annualreviews.orgCategories: General Medicine News, Hem/OncsTweet-
RT @nursariipek: Thrilled to share our latest review on single-cell research exploring various types of leukemia! https://t.co/bFIAkzIsg8 H…
-
Early Findings on Ziftomenib With Chemotherapy in AML From KOMET-007 Trial https://t.co/7s4Iksjmue